Eterna Therapeutics Inc (ERNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has a cash flow conversion efficiency ratio of -1.298x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.15 Million) by net assets ($3.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ERNA market cap for the company's overall valuation and market capitalisation.
Eterna Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Eterna Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eterna Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eterna Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Eterna Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
21st Century Management Services Limited
NSE:21STCENMGM
|
-0.595x |
|
Blockmate Ventures Inc
V:MATE
|
0.102x |
|
Mamba Exploration Ltd
AU:M24
|
-0.144x |
|
Charger Metals NL
AU:CHR
|
-0.019x |
|
Nigbas Nigde Beton Sanayi ve Ticaret AS
IS:NIBAS
|
-0.054x |
|
Sawang Export Public Company Limited
BK:SAWANG
|
0.001x |
|
Innity Corporation Bhd
KLSE:0147
|
-0.154x |
|
NanoVibronix Inc
NASDAQ:NAOV
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Eterna Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Eterna Therapeutics Inc from 2007 to 2025. View current stock price of Eterna Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.40 Million | $-7.02 Million | -2.923x | +68.61% |
| 2024-12-31 | $1.70 Million | $-15.84 Million | -9.310x | -1.87% |
| 2023-12-31 | $2.23 Million | $-20.41 Million | -9.139x | -427.50% |
| 2022-12-31 | $12.11 Million | $-20.98 Million | -1.733x | -88.13% |
| 2021-12-31 | $25.50 Million | $-23.49 Million | -0.921x | +12.93% |
| 2020-12-31 | $7.66 Million | $-8.10 Million | -1.058x | -296.24% |
| 2019-12-31 | $5.09 Million | $2.74 Million | 0.539x | +173.13% |
| 2018-12-31 | $6.92 Million | $1.36 Million | 0.197x | +98.99% |
| 2017-12-31 | $5.54 Million | $549.00K | 0.099x | +1654.00% |
| 2016-12-31 | $4.07 Million | $23.00K | 0.006x | +100.52% |
| 2015-12-31 | $3.85 Million | $-4.18 Million | -1.086x | -85.85% |
| 2014-12-31 | $10.92 Million | $-6.38 Million | -0.584x | -460.25% |
| 2013-12-31 | $9.20 Million | $1.49 Million | 0.162x | -40.59% |
| 2012-12-31 | $7.89 Million | $2.16 Million | 0.273x | +202.14% |
| 2011-12-31 | $6.35 Million | $574.00K | 0.090x | -69.79% |
| 2010-12-31 | $9.46 Million | $2.83 Million | 0.299x | +12.59% |
| 2009-12-31 | $9.42 Million | $2.50 Million | 0.266x | +100.69% |
| 2007-12-31 | $15.57 Million | $-604.00 Million | -38.798x | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for… Read more